OmniParticles operates two distinct services. On the drug substance side we are a CDMO: we develop, refine and scale nanoparticle formulations. On the drug product side we are a CMO by deliberate choice: we do not redesign your formulation. We take the process you define and execute it precisely, repeatably, and under documentation you can file.

Because our drug substance operations work with colloidal and nanoparticle systems every day, formulations that sit outside a standard fill-finish envelope are assessed here rather than declined — but the service remains manufacturing to your process, not developing it.

Company (Headquarters)
South Korea

Types of Drugs Manufactured
Small Molecule;Sterile Fill Finish

CDMO Services 
Research & Development;Regulatory Services;Analytical Development;Process & Forumulation Development

Therapeutic Area
Cardiovascular;Central Nervous System;Immunology;Platform Technologies;Rare and Genetic Disorders

CDMO Number of Facilities
2

Facilities Location
East Asia

Regulatory Approvals for facilities
ISO 9001

Manufacturing Technologies
Sterile Vials